Renascience

Renascience is a Japanese biopharmaceutical company focused on developing innovative medical solutions for aging-related diseases and unmet medical needs. The company's core pipeline centers on RS5614, a small molecule inhibitor of Plasminogen Activator Inhibitor-1 (PAI-1), which is being evaluated for various indications including chronic myeloid leukemia and malignant melanoma. Beyond drug discovery, Renascience develops medical devices and artificial intelligence-based diagnostic tools to support personalized medicine. The company leverages collaborations with academic institutions to translate basic research into clinical applications. Renascience is publicly traded on the Tokyo Stock Exchange and maintains a lean, virtual business model.